Citations

Clear

4847 citation(s) found for "Yu, Eric".

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly, Roisín M. , Leal, Jeffrey P. , Sólnes, Lilja B. , Huang, Chiung‐Yu , Carpenter, Ashley , Gaffney, Katy, Abramson, Vandana G. , Carey, Lisa A. , Liu, Minetta C. , Rimawi, Mothaffar F. , Specht, Jennifer M. , Storniolo, Anna Maria , Valero, Vicente , Krop, Ian E. , Camp, Melissa , Miller, Robert S. , Cimino‐Mathews, Ashley , Stearns, Vered , Abramson, Vandana G , Rimawi, Mothaffar , Specht, Jennifer , Vaklavas, Christos , Krop, Ian E , Winer, Eric , Miller, Robert S , Wolff, Antonio C , Cimino-Mathews, Ashley , Park, Ben Ho , Wahl, Richard L , Stearns, Vered , Carey, Lisa A , Huang, Chiung-Yu , Gaffney, Katy, Winer, Eric P. , Wolff, Antonio C. , Wahl, Richard L.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2021 | Volume: 39 | Issue: 20 | Pages: 2247-2256

10.1200/jco.21.00280 | PMID 33999652 Get It

PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT). PATIENTS AND METHODS Patients with stage II or III, estrogen receptor–negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. 18 F-labeled fluorodeoxyglucose positron emission tomography-computed tomography was performed at baseline and 15 days after PT initiation (C1D15). Eighty evaluable patients were required to test the null hypothesis that the area under the curve of percent change in SULmax by C1D15 predicting pCR is ≤ 0.65, with a one-sided type I error rate of 10%. RESULTS Eighty-eight women were enrolled (83 evaluable), and 85% (75 of 88) completed all four cycles of PT. pCR after PT alone was 22%. Receiver operator characteristic analysis of percent change in SULmax by C1D15 yielded an area under the curve of 0.72 (80% CI, 0.64 to 0.80; one-sided P = .12), which did not reject the null hypothesis. However, between patients who obtained pCR and who did not, a significant difference in median percent reduction in SULmax by C1D15 was observed (63.8% v 41.8%; P = .004) and SULmax reduction ≥ 40% was more prevalent (83% v 52%; P = .03; positive predictive value, 31%). Participants not obtaining a 40% reduction in SULmax by C1D15 were unlikely to obtain pCR (negative predictive value, 91%). CONCLUSION Although the primary objective was not met, early changes in SULmax predict response to PT in estrogen receptor–negative and HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate tailoring of therapy in this setting.
Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity
Kunz, Hawley , Hart, Corey R., Gries, Kevin J. , Parvizi, Mojtaba, LAURENTI, MARCELLO C. , Man, Chiara Dalla , Moore, Natalie , Zhang, Xiaoyan , Ryan, Zachary, Jensen, Michael D. , Kunz, Hawley E., Laurenti, Marcello, Dalla Man, Chiara , Jensen, Michael , Vella, Adrian , Lanza, Ian R , Kunz, Hawley E , Polley, Eric C. , Vella, Adrian , Lanza, Ian R.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | May 17, 2021 | Volume: 321 | Issue: 1 | Pages: E105-E121

10.1152/ajpendo.00070.2021 | PMID 33998291 Get It

Adipose inflammation is proposed to be at the nexus of the systemic inflammation and metabolic derangements associated with obesity. The present study provides evidence to support adipose inflammation as a central feature of the pathophysiology of obesity. Adipose inflammation is associated with systemic and peripheral metabolic derangements, including increased systemic inflammation, reduced insulin sensitivity and reduced skeletal muscle mitochondrial respiration.
Posterior-First Two-Stage Approach to En Bloc Resection of Locally Recurrent Rectal Cancer Involving the Pelvic Sidewall
Sakata, Shinichiro , Karim, S. Mohammed, Mathis, Kellie L. , Rose, Peter S. , Dozois, Eric J. , Kelley, Scott R.

Mayo Clinic

Diseases of the Colon & Rectum | May 15, 2021 | Volume: 64 | Issue: 8 | Pages: e465-e470

10.1097/dcr.0000000000002091 | PMID 34214058 Get It

INTRODUCTION: Using standard anterior-only or anterior then posterior approaches can make an R0 resection difficult to achieve in patients with pelvic sidewall recurrences because of confined working spaces and poor visibility. TECHNIQUE: Given the limitations of standard approaches, we have used a novel posterior-first then anterior 2-stage approach allowing us to widely expose and secure deep margins and control vessels under direct visualization. RESULTS: We present a technical note describing this approach in patients with recurrent rectal cancer involving the pelvic sidewall with extrapelvic extension. CONCLUSION: The posterior-first approach may assist in achieving a higher number of R0 resections in patients with locally recurrent rectal cancer involving the pelvic sidewall.
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Ballman, Karla A., Halabi, Susan , Atherton, Pamela J., Mortazavi, Amir , Sweeney, Christopher J. , Stadler, Walter M. , Teply, Benjamin A. , Picus, Joel , Tagawa, Scott T. , Katragadda, Sreedhar , Vaena, Daniel A. , Misleh, Jamal , Flaig, Thomas W. , Bajorin, Dean F. , Hahn, Olwen, Rosenberg, Jonathan E , Halabi, Susan , Mortazavi, Amir , Sweeney, Christopher , Stadler, Walter M , Teply, Benjamin A , Picus, Joel , Tagawa, Scott T , Hoimes, Christopher , Flaig, Thomas W , Bajorin, Dean , Morris, Michael J , Ballman, Karla A., Atherton, Pamela J., Plimack, Elizabeth R. , Dreicer, Robert , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | May 14, 2021 | Volume: 39 | Issue: 22 | Pages: 2486-2496

10.1200/jco.21.00286 | PMID 33989025 Get It

PURPOSE The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial was performed with the primary objective of testing whether patients treated with GC and bevacizumab (GCB) have superior overall survival (OS) than patients treated with GC and placebo (GCP). PATIENTS AND METHODS Between July 2009 and December 2014, 506 patients with metastatic urothelial carcinoma without prior chemotherapy for metastatic disease and no neoadjuvant or adjuvant chemotherapy within 12 months were randomly assigned to receive either GCB or GCP. The primary end point was OS, with secondary end points of progression-free survival, objective response, and toxicity. RESULTS With a median follow-up of 76.3 months among alive patients, the median OS was 14.5 months for patients treated with GCB and 14.3 months for patients treated with GCP (hazard ratio for death = 0.87; 95% CI, 0.72 to 1.05; two-sided stratified log-rank P = .14). The median progression-free survival was 8.0 months for GCB and 6.7 months for GCP (hazard ratio = 0.77; 95% CI, 0.63 to 0.95; P = .016). The proportion of patients with grade 3 or greater adverse events did not differ significantly between both arms, although increased bevacizumab-related toxicities such as hypertension and proteinuria occurred in the bevacizumab-treated arm. CONCLUSION The addition of bevacizumab to GC did not result in improved OS. The observed median OS of about 14 months is consistent with prior phase III trials of cisplatin-based chemotherapy.
Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Surface Roughness of Titanium Orthopedic Implants Alters the Biological Phenotype of Human Mesenchymal Stromal Cells
Trousdale, William H. , Thaler, Roman , Xu, Wei , Denbeigh, Janet M. , Nair, Asha, Kocher, Jean‐Pierre , Dudakovic, Amel , Berry, Daniel J., Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Xu, Wei , van Wijnen, Andre J , Berry, Daniel J , Yao, Jie , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Tissue Engineering Part A | May 12, 2021 | Volume: 27 | Issue: 23-24 | Pages: 1503-1516

10.1089/ten.tea.2020.0369 | PMID 33975459 Get It

Histological evaluation of acute ischemic stroke thrombi may indicate the occurrence of vessel wall injury during mechanical thrombectomy
Mereuta, Oana Madalina , Abbasi, Mehdi , Fitzgerald, Seán , Dai, Daying , Kadirvel, Ram , Almekhlafi, Mohammed , Kvamme, Peter , Gounis, Matthew J. , Patel, Biraj M. , Aghaebrahim, Amin, Sauvageau, Eric , Bhuva, Parita, Soomro, Jazba , Thacker, Ike, Copelan, Alexander , Nazari, Pouya , Cantrell, Donald R. , Mohammaden, Mahmoud , Pisani, Leonardo , Puri, Ajit S , Meves, Alexander , Larco, Jorge Arturo , Cloft, Harry J. , Kallmes, David F. , Doyle, Karen , Brinjikji, Waleed , Almekhlafi, Mohammed A , Mendes Pereira, Vitor , Jahromi, Babak S , Gounis, Matthew J , Nazari, Pouya , Al-Bayati, Alhamza , Pisani, Leonardo , Rodrigues, Gabriel Martins , Arturo Larco, Jorge L , Savastano, Luis , Doyle, Karen M , Brinjikji, Waleed , Patel, Biraj M , Fitzgerald, Seán , Dai, Daying , Madalina Mereuta, Oana , Kadirvel, Ramanathan , Hanel, Ricardó A. , Yoo, Albert J. , Layton, Kennith F. , Almandoz, Josser E Delgado , Jahromi, Babak S. , Nogueira, Raul G. , Demchuk, Andrew M. , Kayan, Yasha , Haussen, Diogo C , Al‐Bayati, Alhamza R , Entwistle, John

Mayo Clinic

Journal of NeuroInterventional Surgery | May 11, 2021 | Volume: 14 | Issue: 4 | Pages: 356-361

10.1136/neurintsurg-2021-017310 | PMID 33975922 Get It

Background Several animal studies have demonstrated that mechanical thrombectomy (MT) for acute ischemic stroke (AIS) may cause vessel wall injury (VWI). However, the histological changes in human cerebral arteries following MT are difficult to determine. Objective To investigate the occurrence of VWI during MT by histological and immunohistochemical evaluation of AIS clots. Methods As part of the multicenter STRIP registry, 277 clots from 237 patients were analyzed using Martius Scarlett Blue stain and immunohistochemistry for CD34 (endothelial cells) and smooth muscle actin (smooth muscle cells). Results MT devices used were aspiration catheters (100 cases), stentriever (101 cases), and both (36 cases). VWI was found in 33/277 clots (12%). There was no significant correlation between VWI and MT device. The degree of damage varied from grade I (mild intimal damage, 24 clots), to grade II (relevant intimal and subintimal damage, 3 clots), and III (severe injury, 6 clots). VWI clots contained significantly more erythrocytes (p=0.006*) and less platelets/other (p=0.005*) than non-VWI clots suggesting soft thrombus material. Thrombolysis correlated with a lower rate of VWI (p=0.04*). VWI cases showed a significantly higher number of passes (2 [1–4] vs 1 [1–3], p=0.028*) and poorer recanalization outcome (p=0.01*) than cases without VWI. Conclusions Histological markers of VWI were present in 12% of AIS thrombi, suggesting that VWI might be related to MT. VWI was associated with soft thrombus consistency, higher number of passes and poorer revascularization outcome. There was no significant correlation between VWI and MT device.
Abstract 17014: Cardiologist Assessment and Approval Was the Primary Predictor of Kidney Transplant Candidacy and Transplantation Among Patients With Reduced Left Ventricular Ejection Fraction
Madden, Michelle , Gallen, Rory , LeMond, Lisa , Steidley, D. Eric , Keddis, Mira T.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.17014 Get It

Introduction: End stage renal disease (ESRD) patients with concomitant heart failure (HF) are often denied kidney transplantation (KTx). The aims of this study were to explore factors predictive of suitability for KTx and to assess cardiovascular (CV) outcomes in patients with impaired left ventricular ejection fraction (LVEF) presenting for KTx evaluation. Methods: We evaluated 109 consecutive adults with LVEF≤40% at the time of initial KTx evaluation between 2013 and 2018. Post-transplant CV outcomes were defined as non-fatal MI, admission for HF, CV death and all-cause mortality. Results: Mean age was 58.2 years (SD11.9), 78% were male, 58% had diabetes, 70% had history of CV events and 42% had ischemic cardiomyopathy. Mean LVEF was 31.5% (SD 6.47). Eighty patients had nuclear stress imaging; 10% were positive for reversible ischemia and 43% for prior infarct. Mean VO2max was 14.4(SD 5.71)ml/kg/min (31 patients). A cardiologist evaluated 93% of patients and was present at 58% of selection committee meetings. Twenty-four patients (22%) were denied by a cardiologist for KTx and 59 (54%) were denied by the selection committee, of whom 43 were due to CV risk. On univariate analysis, the variables associated with denial for KTx were: cardiologist denial, denial due to CV risk, Native American race (6% of cohort), higher NT-pro-BNP, prior MI, coronary intervention, positive stress study, anemia, lower EF and lower VO2max (all p<0.05). On multivariate analysis, cardiologist denial was the only significant predictor of denial for KTx (OR: 29.4, p=0.0007). At median follow-up of 15 months, 5 (5%) suffered non-fatal MI, 13 (12%) were hospitalized for HF exacerbation and 17 (16%) died. Only 22 (20%) underwent KTx. Post-KTx, there was one death, one non-fatal MI and 3 hospitalizations for HF. Mean LVEF improvement was 16% (SD12.9). Conclusions: Only 38% of ESRD patients with LVEF≤40% presenting for KTx evaluation were approved and of those, only 52% received KTx. Cardiologist approval was the primary predictor of suitability for KTx. Despite careful selection, prevalence of CV events and mortality after KTx was 23%. There is need for a consistent multidisciplinary approach during KTx evaluation, including cardiologist input, to improve CV outcomes.
Abstract 15728: Machine Learning Helps Predict Short and Intermediate-term Risk for All Cause Mortality in Patients Undergoing Percutaneous Coronary Intervention
Wang, Panwen , Pujari, Sai Harika , Fortuin, F. David , Eleid, Mackram F. , Beohar, Nirat , Mookadam, Farouk , Holmes, David R. , Agasthi, Pradyumna , Ashraf, Hasan, Chao, Chieh‐Ju , Allam, Mohamed , Yang, Eric H. , Mookadam, Farouk , Arsanjani, Reza

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15728 Get It

Background: Identifying patients at a high risk of mortality post percutaneous coronary intervention (PCI) is of vital clinical importance. We investigated the utility of machine learning algorithms to predict short and intermediate-term risk of all-cause mortality in patients undergoing PCI. Methods: Patient-level demographics, clinical, electrocardiographic ,echocardiographic and angiographic data from January 2006 to December 2017 were extracted from the Mayo Clinic CathPCI registry and clinical records. For patients with multiple PCI events, data collected at the time of the index PCI was used for analysis. Patients who underwent bailout coronary artery bypass graft surgery (CABG) prior to discharge were excluded. 306 variables were incorporated into random forest machine learning model (RF) to predict all-cause mortality at 6 months and 1 year after PCI. Ten-fold cross-validation repeated five times was used to optimize the hyperparameters and estimate its external performance. The National Cardiovascular Data Registry (NCDR) based logistic regression model was used for comparison. The area under receiver operator characteristic curves (AUC) was calculated to assess the ability of the models to predict all-cause mortality. Results: A total of 17356 unique patients were included for the final analysis after excluding 165 patients who underwent CABG surgery during the index hospitalization. The mean age was 66.9 ± 12.5 years;71% were male. Indications for PCI were ST-elevation myocardial infarction (9.4%), non-ST elevation myocardial infarction (12.9%), unstable angina (17.7%), and stable angina (52.8%) in the cohort. In-hospital, 6-month & 1 year mortality rates were 1.9%,4.2% & 5.8% respectively. The RF model was superior to the NCDR model in predicting inhospital, 6-month, 1 year mortality (p<0.0001) ( Figure 1 ). Conclusion: Machine learning is superior to NCDR model in predicting short and intermediate risk of all-cause mortality post PCI.
Abstract 15209: LPA Variants Are Associated With Aortic Valve Stenosis, Heart Failure and Chronic Kidney Disease
Satterfield, Benjamin A. , Clarke, Shoa L., Tcheandjieu, Catherine , Zhu, Xiang , Bastarache, Lisa , Larson, Eric B. , Shang, Ning , Rosenthal, Elisabeth A. , Namjou‐Khales, Bahram, Wei, Wei‐Qi, Hebbring, Scott J. , Manolio, Teri A. , Satterfield, Benjamin A , Dikilitas, Ozan , Safarova, Maya , Clarke, Shoa L. , Justice, Anne E. , Shah, Amy S. , Urbina, Elaine M. , Feng, QiPing , Jarvik, Gail P. , Andrade, Mariza de , Assimes, Themistocles L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15209 Get It

Background: The pathophysiology of lipoprotein (a) [Lp(a)] remains obscure. We conducted a phenome wide analysis study (PheWAS) to identify pleiotropic effects of LPA variants. Methods: Among 51,843 European-ancestry participants (age 58±16 years, 54% female) of the electronic MEdical Records and Genomics (eMERGE) network we assessed whether LPA variants exhibited pleiotropic affects through an electronic health record-based PheWAS. We adjusted significant associations by presence of atherosclerotic cardiovascular disease (ASCVD; defined as a composite of coronary heart disease, cerebrovascular disease, and peripheral artery disease) to determine whether those associations were independent of ASCVD. Results: In PheWAS analysis, we tested 864 phecodes with 36 independent LPA variants. We identified 21 significant associations with non-ASCVD phenotypes including heart failure, aortic valve stenosis, and chronic kidney disease of which 14 were replicated across independent cohorts. The strength of associations between the LPA variant rs10455872 and both heart failure and aortic valve stenosis related phecodes were significantly attenuated after adjustment for ASCVD. However, the association with chronic kidney disease phecode remained independent following adjustment for ASCVD without any attenuation in the estimated odds ratio (Table). Conclusions: LPA genetic variants were associated with aortic valve stenosis, heart failure and chronic kidney disease. The observed association of LPA variant rs10455872 with aortic stenosis and heart failure appear to be partially mediated by ASCVD, while the association with chronic kidney disease appears to be independent of ASCVD. Additional studies are needed to elucidate potential mechanisms by which Lp(a) may contribute to the pathogenesis of non-ASCVD disease phenotypes.